(MENAFN- Straits Research)
Pemetrexed Market Size, Share & Growth Analysis
The global pemetrexed market size was valued at USD 2.38 billion in 2025 and is projected to grow from USD 2.42 billion in 2026 to USD 2.75 billion by 2034, registering a CAGR of 1.6% during the forecast period from 2026 to 2034. North America dominated the pemetrexed market with a market share of 41.59% in 2025.
Pemetrexed is an antifolate chemotherapy drug used to treat certain types of cancer by interfering with folate-dependent processes required for cancer-cell growth and replication. It is primarily used in the treatment of non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, either alone or in combination with other anticancer therapies such as platinum-based chemotherapy and immunotherapy. Pemetrexed is generally administered as an intravenous injection and is available in various formulations and strengths.
Pemetrexed Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 2.38 Billion
2026 Market Size: USD 2.42 Billion
2034 Projected Market Size: USD 2.75 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 1.6%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 41.59%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 7.5%
Segment Insights
By Application Share
Leading Segment: Non-Squamous NSCLC
Market Share in 2025: 75%
By End-User Share
Fastest-Growing Segment: Online Pharmacies
CAGR: 7.5% (2026–2034)
Download a Free Sample To learn more about this report,
Pemetrexed Market Trends
Pemetrexed Treatment Is Shifting Toward Combination Regimens With Immunotherapy
The pemetrexed market is shifting from conventional chemotherapy use toward combination-based treatment regimens that integrate pemetrexed with immune checkpoint inhibitors and platinum chemotherapy. Pemetrexed remains an established component of first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC), where it can be administered with pembrolizumab and platinum chemotherapy. This integration is strengthening pemetrexed's role within broader oncology treatment protocols rather than positioning it solely as an independent chemotherapy agent.
The shift toward combination therapy is also changing the role of pemetrexed during maintenance treatment. Clinical practice increasingly evaluates whether pemetrexed should be continued alongside immunotherapy after initial combination treatment, with treatment decisions becoming more dependent on patient characteristics, efficacy, toxicity, and treatment response. Recent real-world evidence has questioned the incremental benefit of continuing pemetrexed with pembrolizumab during maintenance, indicating that future use may become more selectively tailored to individual treatment strategies.
April 2025 - Amneal Pharmaceuticals: The company launched PEMRYDI RTU, a ready-to-use pemetrexed injection designed to eliminate reconstitution and dilution requirements. The 500 mg/50 mL presentation demonstrates how manufacturers are adapting pemetrexed products to improve preparation efficiency and workflow within hospital-based oncology treatment.
Pemetrexed Market Dynamics
Market Drivers
Growing Use of Combination Chemotherapy Sustains Demand for Pemetrexed
The continued use of pemetrexed-based combination regimens in non-squamous non-small cell lung cancer (NSCLC) is supporting demand for pemetrexed across oncology treatment pathways. Pemetrexed is used in combination with pembrolizumab and platinum chemotherapy for the initial treatment of eligible patients with metastatic non-squamous NSCLC and with cisplatin for locally advanced or metastatic disease. Its established role in combination treatment gives pemetrexed a recurring position within multi-cycle chemotherapy protocols.
Clinical treatment guidelines continue to include pemetrexed-based combinations as recommended options for advanced NSCLC without driver alterations. This supports continued use of pemetrexed alongside immunotherapy and platinum chemotherapy rather than limiting the drug to standalone chemotherapy applications.
January 2025 - Johnson & Johnson: Health Canada issued a Notice of Compliance for RYBREVANT (amivantamab) in combination with carboplatin and pemetrexed for certain patients with locally advanced or metastatic NSCLC. The regulatory development reinforced the continued integration of pemetrexed into combination-based oncology treatment pathways and supported its ongoing relevance in evolving lung-cancer treatment protocols.
Market Restraints
Generic Competition Creates Pricing Pressure for Pemetrexed Products
Intensifying generic competition is placing downward pressure on pemetrexed prices and limiting revenue opportunities for manufacturers. Pemetrexed is an established injectable chemotherapy, and the availability of multiple generic suppliers allows hospitals, healthcare systems, and procurement organizations to prioritize lower-cost alternatives. As more manufacturers compete for the same oncology contracts, price becomes an increasingly important purchasing factor.
The impact is particularly pronounced in markets where procurement is conducted through competitive tenders. Greater generic availability can reduce branded-product market share and compress manufacturer margins, making it more difficult for companies to generate premium pricing from established pemetrexed formulations.
2025–2026 - Generic Injectable Suppliers: Continued competition among established oncology-drug manufacturers and generic injectable suppliers has increased pressure on pemetrexed pricing, particularly in hospital and institutional procurement channels. Suppliers are increasingly required to compete on acquisition cost, regulatory compliance, product quality, and supply reliability, limiting the ability to sustain premium pricing for standard pemetrexed formulations.
Market Opportunity
Ready-to-Use Injectable Formulations Create Opportunities to Improve Oncology Treatment Efficiency
The development of ready-to-use (RTU) pemetrexed injections creates an opportunity for manufacturers to differentiate established chemotherapy products through improved preparation and administration efficiency. Conventional injectable preparation can require reconstitution and dilution before administration, whereas RTU presentations can reduce preparation steps and potentially improve workflow within hospital oncology and infusion settings.
This opportunity is particularly relevant as healthcare providers seek to improve operational efficiency while maintaining reliable access to essential injectable oncology medicines. Manufacturers that combine established pemetrexed efficacy with convenient presentation formats can differentiate their products beyond price and compete for hospital and oncology-center procurement.
2025–2026 - Injectable Oncology Product Developers: Recent market activity has continued to emphasize ready-to-use and administration-efficient injectable presentations as a means of improving hospital workflow. These developments demonstrate that formulation convenience remains an important opportunity for pemetrexed suppliers seeking to differentiate products in an increasingly competitive generic injectable market.
Market Challenges
Sterile Injectable Manufacturing Requirements Increase Production Complexity
Pemetrexed manufacturers face the challenge of maintaining stringent quality and sterility requirements while producing injectable oncology medicines at commercially competitive costs. Injectable products require controlled manufacturing environments, specialized equipment, quality testing, and strict regulatory compliance, increasing the operational requirements compared with simpler oral dosage forms.
The challenge becomes more pronounced as generic competition intensifies and selling prices decline. Manufacturers must maintain product quality and reliable supply while controlling production costs sufficiently to remain competitive in tenders and hospital procurement programs. This creates pressure to improve manufacturing efficiency, optimize capacity utilization, and invest in specialized injectable production capabilities.
October 2025 - Amneal Pharmaceuticals: The company reported expanded manufacturing capacity across four sites and 21 manufacturing lines, including capabilities for cytotoxic oncology products and ready-to-use presentations. The investment illustrates the scale of manufacturing infrastructure required to compete in the injectable oncology market and maintain reliable supply.
Pemetrexed Market Segmentation Analysis
Non-Squamous NSCLC Leads the Pemetrexed Market With 75% Share in 2025
By application, the pemetrexed market is segmented into Malignant Pleural Mesothelioma and Non-Squamous Non-Small Cell Lung Cancer (NSCLC). The Non-Squamous NSCLC segment held the leading position, accounting for 75% of the market in 2025. Its dominance is supported by the established use of pemetrexed across multiple stages of non-squamous NSCLC treatment, including initial treatment, combination therapy, maintenance therapy, and treatment of recurrent metastatic disease.
Pemetrexed is indicated in combination with pembrolizumab and platinum chemotherapy for the initial treatment of eligible patients with metastatic non-squamous NSCLC. It is also used with cisplatin for locally advanced or metastatic disease and as a single agent for maintenance treatment following platinum-based chemotherapy. This broad treatment role creates a larger and more recurring application base than malignant pleural mesothelioma, where pemetrexed is primarily used with cisplatin for initial treatment.
Request Customization to receive a tailored report.
Online Pharmacies Are the Fastest-Growing End-User Segment at 7.5% CAGR
By end user, the pemetrexed market is segmented into Hospitals, Oncology Centers, Online Pharmacies, and Offline Pharmacies. Online Pharmacies are projected to be the fastest-growing segment, registering a 7.5% CAGR from 2026 to 2034. The segment's expansion is supported by the broader shift toward digital pharmaceutical purchasing, which provides patients and caregivers with convenient access to prescription medicines and allows pharmacies to extend their reach beyond physical locations.
Online pharmacy platforms can improve product accessibility through digital ordering, prescription management, home delivery, and broader product availability. These capabilities are particularly relevant to patients undergoing long-term cancer treatment who may require repeated access to prescribed medicines. As digital healthcare infrastructure and prescription fulfillment services expand, online channels can capture a larger share of pharmaceutical distribution.
Speak to an Analyst to discuss market opportunities.
Pemetrexed Market Regional Overview
North America Pemetrexed Market Analysis
North America held the largest regional position in the pemetrexed market in 2025, accounting for 40% of the market, with a value of USD 0.95 billion and a projected CAGR of 5.8% from 2026 to 2034. The region's leading position is supported by advanced oncology infrastructure, a high prevalence of lung cancer, established hospital and oncology-center networks, and broad access to chemotherapy. Pemetrexed remains an important component of treatment regimens for non-squamous non-small cell lung cancer (NSCLC), supporting recurring demand from institutional healthcare providers.
United States Pemetrexed Market Insights
The United States is the leading country market in North America, supported by its extensive oncology-care network, high healthcare expenditure, and established use of pemetrexed in NSCLC and malignant pleural mesothelioma treatment. Hospitals and oncology centers remain important procurement channels because pemetrexed is administered intravenously under healthcare supervision. The availability of generic formulations has also expanded access while increasing competition among suppliers.
Canada Pemetrexed Market Insights
Canada benefits from an established publicly funded healthcare system and specialized oncology centers that provide chemotherapy for lung cancer and other thoracic malignancies. Pemetrexed is used within combination treatment protocols for eligible patients with non-squamous NSCLC, creating demand through hospital and cancer-center procurement.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Pemetrexed Market Analysis
Europe accounted for 28% of the pemetrexed market in 2025, representing a market value of USD 0.67 billion, and is projected to grow at a 5.5% CAGR from 2026 to 2034. The region's established healthcare systems, specialized oncology centers, and widespread access to chemotherapy support continued pemetrexed consumption. Germany, the United Kingdom, France, Italy, and Spain represent important country markets within the region.
Germany Pemetrexed Market Insights
Germany represents one of Europe's major pemetrexed markets, supported by its advanced healthcare infrastructure, specialized cancer centers, and established pharmaceutical industry. Pemetrexed is used in oncology treatment pathways for non-squamous NSCLC and malignant pleural mesothelioma, generating demand through hospitals and specialist treatment centers.
United Kingdom Pemetrexed Market Insights
The United Kingdom has an established oncology-care system supported by specialized cancer centers and national healthcare procurement. Pemetrexed is used as part of treatment regimens for non-squamous NSCLC and mesothelioma, creating a recurring institutional demand base.
Asia Pacific Pemetrexed Market Analysis
Asia Pacific accounted for 22% of the pemetrexed market in 2025, with a market value of USD 0.52 billion, and is projected to register the fastest regional growth at a 7.5% CAGR from 2026 to 2034. Growth is supported by the region's large cancer patient population, increasing oncology-treatment capacity, expanding healthcare infrastructure, and greater access to chemotherapy. Market research identifies China, Japan, India, South Korea, Australia, and Southeast Asian countries as important markets in the region.
China Pemetrexed Market Insights
China is a major Asia Pacific market because of its large cancer patient population and expanding oncology-care infrastructure. The country accounts for approximately one-quarter of the global cancer burden, with more than five million new cancer cases diagnosed annually. Lung cancer is among the major cancers contributing to this burden, creating a substantial patient population requiring systemic oncology treatment.
Japan Pemetrexed Market Insights
Japan has an established oncology treatment system supported by advanced hospitals, specialized cancer centers, and high access to pharmaceutical therapies. Lung cancer represents an important cancer burden in the country, supporting demand for established NSCLC treatment regimens that include pemetrexed.
Middle East & Africa Pemetrexed Market Analysis
The Middle East & Africa accounted for 6% of the pemetrexed market in 2025, representing USD 0.14 billion, and is projected to grow at a 6.8% CAGR from 2026 to 2034. Growth is supported by increasing cancer prevalence, healthcare infrastructure investment, and the expansion of specialized oncology services. Saudi Arabia, the UAE, South Africa, Iran, and Egypt represent important country markets.
Saudi Arabia Pemetrexed Market Insights
Saudi Arabia represents an important Middle Eastern market because of its expanding healthcare infrastructure and investment in specialized medical services. The development of advanced hospitals and oncology centers is increasing access to cancer diagnosis and treatment, creating demand for established chemotherapy medicines.
United Arab Emirates Pemetrexed Market Insights
The UAE benefits from developed healthcare infrastructure, specialized hospitals, and a growing private healthcare sector. These factors support access to advanced oncology treatment and create demand for injectable chemotherapy products such as pemetrexed.
South America Pemetrexed Market Analysis
South America accounted for 4% of the pemetrexed market in 2025, equivalent to USD 0.10 billion, and is projected to expand at a 6.0% CAGR from 2026 to 2034. Brazil, Argentina, Chile, and Peru are among the key country markets covered for the region.
Brazil Pemetrexed Market Insights
Brazil represents the largest potential market in South America because of its large population and comparatively extensive healthcare and oncology infrastructure. Demand for pemetrexed is primarily linked to treatment of non-squamous NSCLC and other eligible thoracic malignancies.
Argentina Pemetrexed Market Insights
Argentina has an established pharmaceutical and healthcare system with specialized oncology facilities concentrated in major population centers. Pemetrexed demand is supported by the treatment of NSCLC and mesothelioma through hospital and oncology-center channels.
Competitive Landscape
The Pemetrexed Market is characterized by competition between established pharmaceutical companies, generic drug manufacturers, and specialty injectable-drug suppliers. The competitive environment is shaped by product availability, regulatory approvals, manufacturing capabilities, pricing, supply reliability, and the ability to serve hospitals and oncology centers with consistent-quality injectable products. The market includes both originator and generic suppliers, with generic availability increasing competition and giving healthcare providers more cost-effective treatment options. Key market participants include Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., Fresenius Kabi USA, Teva Pharmaceuticals USA Inc., Biocon, Pfizer Inc., Apotex Inc., Dr. Reddy's Laboratories Ltd., and Cadila Pharmaceuticals.
Amneal Pharmaceuticals
The company launched PEMRYDI RTU, a ready-to-use pemetrexed injection designed to eliminate reconstitution and dilution requirements. Although Amneal is outside the specified company list, the launch demonstrates the direction of competitive development in the pemetrexed market, where manufacturers are differentiating established products through more convenient injectable presentations and improved hospital workflow.
List of Key and Emerging Players in Pemetrexed Market
Eli Lilly and Company
Stada Arzneimittel AG
Eagle Pharmaceuticals, Inc
Fresenius Kabi USA
Teva Pharmaceuticals USA Inc
Biocon
Pfizer Inc.
Apotex Inc
Dr. Reddys Laboratories Ltd
Cadila Pharmaceuticals.
Accord Healthcare
Accure Labs Pvt. Ltd
Shanghai Henlius Biotech, Inc.
Janssen Global Services LLC
Checkpoint Therapeutics, Inc.
Key Industry Developments
April 2026: Fresenius Kabi expanded its injectable oncology portfolio by increasing the production and distribution of pemetrexed for injection to meet growing demand from hospitals and cancer treatment centers.
February 2026: Hikma Pharmaceuticals strengthened its oncology business by expanding the supply of generic pemetrexed formulations across key international markets, enhancing access to cost-effective cancer therapies.
September 2025: Sun Pharmaceutical Industries expanded its oncology portfolio by introducing additional generic pemetrexed presentations for the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.
May 2025: Teva Pharmaceuticals strengthened its injectable oncology portfolio by expanding the commercialization of generic pemetrexed products, supporting broader availability of chemotherapy treatments in regulated markets.
Report Scope
Comments
No comment